Key result
Antisense oligonucleotides emerge as promising therapies for disorders driven by specific genetic factors.
Why the study?
Antisense oligonucleotides have complex production processes and present off-target reactions, requiring a review of their pharmaceutical characteristics and clinical applicability.
Antisense oligonucleotides represent a promising and increasingly approved therapeutic approach for specific genetic and neurodegenerative disorders.
No takes yet. Share an insight, caveat, or question.
May support ASO consideration in select genetic disorders; leaves open optimal selection and long-term validation.
Araya et al. (2023) conducted a review in Genetic, neurodegenerative, neuromuscular, and oncological diseases. Antisense oligonucleotides (ASOs) was evaluated. Antisense oligonucleotides represent a promising therapeutic approach for disorders driven by specific genetic factors, with several drugs already approved for commercialization.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: